Natera (NASDAQ:NTRA) Announces Earnings Results

Natera (NASDAQ:NTRA) released its quarterly earnings results on Thursday. The medical research company reported ($0.41) earnings per share for the quarter, topping the consensus estimate of ($0.42) by $0.01, Zacks reports. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The company had revenue of $476.10 million during the quarter, compared to the consensus estimate of $447.91 million. Natera updated its FY 2025 guidance to EPS.

Natera Trading Down 0.7 %

NASDAQ NTRA opened at $155.59 on Friday. The company has a debt-to-equity ratio of 0.33, a quick ratio of 4.23 and a current ratio of 4.39. Natera has a one year low of $83.13 and a one year high of $183.00. The company’s 50 day moving average price is $167.44 and its 200 day moving average price is $146.95. The firm has a market capitalization of $20.54 billion, a price-to-earnings ratio of -88.40 and a beta of 1.66.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the stock. The Goldman Sachs Group boosted their target price on shares of Natera from $160.00 to $190.00 and gave the company a “buy” rating in a research note on Tuesday, January 28th. JPMorgan Chase & Co. lifted their price target on shares of Natera from $160.00 to $200.00 and gave the stock an “overweight” rating in a report on Friday, December 13th. Sanford C. Bernstein upped their price objective on shares of Natera from $160.00 to $200.00 and gave the company an “outperform” rating in a research note on Friday, January 10th. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $180.00 target price on shares of Natera in a research note on Wednesday. Finally, Morgan Stanley boosted their price target on Natera from $132.00 to $176.00 and gave the company an “overweight” rating in a report on Thursday, November 14th. One analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $172.69.

Insiders Place Their Bets

In other Natera news, insider Solomon Moshkevich sold 4,858 shares of the business’s stock in a transaction dated Monday, December 9th. The stock was sold at an average price of $166.59, for a total transaction of $809,294.22. Following the transaction, the insider now owns 114,912 shares in the company, valued at $19,143,190.08. The trade was a 4.06 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Roelof Botha sold 87,473 shares of the stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $169.12, for a total value of $14,793,433.76. Following the completion of the sale, the director now owns 1,224,787 shares of the company’s stock, valued at approximately $207,135,977.44. This trade represents a 6.67 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 295,772 shares of company stock worth $49,741,699 over the last ninety days. 7.60% of the stock is owned by company insiders.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.